XTalks

JULY 28, 2021

Merck has scored US Food and Drug Administration (FDA) approval for its next-generation pneumonia vaccine Vaxneuvance that covers 15 different strains of the pneumococcal bacteria that causes the infection. Both next-gen shots offer enhanced protection against bacteria that can cause pneumonia, blood infections and meningitis.

FDA Approval 89

FDA Approval Vaccination Vaccine Immune Response 89

Pharmaceutical Technology

MAY 18, 2023

An investigational orally delivered biologic drug, LMN-201 is a cocktail of four therapeutic proteins that act synergistically to neutralise the C difficile bacterium and the toxin. Pivotal trials on LMN-201 are expected to commence in 2023. It is compatible with standard-of-care antibiotics.

Bacterium 130

Bacterium Bacteria FDA Approval Trials 130

XTalks

JULY 25, 2023

Anthrax is a rare, yet severe disease caused by the bacterium B. The bacteria usually enter the body through wounds, but infection can also occur through contaminated meat or inhalation of spores. Moreover, the clinical trials demonstrated that Cyfendus exhibited a favorable tolerability profile. What Is Anthrax?

FDA Approval 98

FDA Approval Vaccination Vaccine Antibody 98

Pharmaceutical Technology

OCTOBER 28, 2022

The company says that these four serotypes represent roughly 10–15% of bacteria causing pneumococcal disease in adults. While the first pneumococcal polysaccharide vaccine was approved in the US in 1977, the first conjugate shot Prevnar was greenlighted only in 2000.

Vaccination 162

Vaccination Vaccine Marketing Bacteria 162

pharmaphorum

JULY 2, 2021

Under the terms of the new deal, Nestle’s Health Sciences unit will pay Seres another $125 million if the FDA approves the drug – called SER-109 – and is also line for up to $225 million in commercial milestones tied to sales targets. diff coming through clinical trials, some of which also have deep-pocketed partners.

Bacterium 69

Bacterium Drugs Bacteria FDA Approval 69

XTalks

AUGUST 2, 2023

Paxlovid was first authorized under the FDA Emergency Use Authorization in December 2021 ; however, it has received FDA approval on May 25, 2023. pneumoniae serotypes) replaced the company’s first pneumococcal conjugate vaccine Prevnar (PCV7, approved by the FDA in February 2000) in a February 2010 FDA approval.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

XTalks

DECEMBER 24, 2020

As of November, the WHO has discouraged the use of the drug as the agency’s review of data from four different clinical trials yielded no worthy effect on mortality, need for mechanical ventilation, time to clinical improvement or any other important patient outcomes.

Life Science 111

Life Science Vaccination Vaccine Gene 111